Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
76.90
-0.14 (-0.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
43
44
Next >
Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings
July 26, 2023
Argenx is up around 40% in 2023 after shares soared nearly 30% in a single day last week.
Via
Investor's Business Daily
Dow Jones Leads Weekly Gains As Tesla, Netflix Sell-Offs Dent Nasdaq; Big Banks Show Resilience To Volatility
July 21, 2023
Via
Benzinga
Why Pieris Pharmaceuticals Shares Shooting Higher Today?
July 18, 2023
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company
Via
Benzinga
NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories
July 18, 2023
Wall Street Journal
Via
Benzinga
This Is What Whales Are Betting On AstraZeneca
July 13, 2023
Via
Benzinga
AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants
July 18, 2023
The FDA approved AstraZeneca Plc (NASDAQ:
Via
Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
July 17, 2023
The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030.
Via
Benzinga
3 Doomed Biotech Stocks Destined for Disaster
July 17, 2023
Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures.
Via
InvestorPlace
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
July 13, 2023
An overweight world is hungry for new treatments. For now, two companies own the market.
Via
Investor's Business Daily
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
July 12, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
A Look Into AstraZeneca's Debt
July 07, 2023
Via
Benzinga
AstraZeneca Unusual Options Activity
July 03, 2023
Via
Benzinga
AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment
July 03, 2023
The company tested a treatment in combination with Daiichi Sankyo.
Via
Investor's Business Daily
50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
July 11, 2023
One in eight women will be diagnosed with breast cancer during
Via
Benzinga
What's Going On With Novavax (NVAX) Stock?
July 10, 2023
Novavax, Inc. (NASDAQ: NVAX) shares are trading higher on Monday after the company announced an amendment to its Canada supply agreement, under which the Government of Canada will pay Novavax $349.6...
Via
Benzinga
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review
July 07, 2023
Automakers rallied on sales while Meta's Threads had a big launch.
Via
Investor's Business Daily
Biotech Blues: Stay Balanced Through July Earnings Season
July 05, 2023
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts.
Via
Talk Markets
These Were Monday's 2 Stock Movers That Investors Cared About the Most
July 03, 2023
On a quiet day on Wall Street, a couple of stocks still saw a considerable amount of activity.
Via
The Motley Fool
AstraZeneca Unusual Options Activity For June 28
June 28, 2023
Via
Benzinga
Price Over Earnings Overview: AstraZeneca
June 27, 2023
Via
Benzinga
Week In Review: AstraZeneca Considers Spinning Off China Ops Into Separate Company
June 24, 2023
Deals, financings, trials and approvals for the week ending June 23.
Via
Talk Markets
AstraZeneca Losses Leave The FTSE In The Red To Start July
July 03, 2023
Despite reaching record highs earlier this year, the UK's FTSE 100 experienced a decline in the April-June period due to volatile commodity prices and persistent inflation concerns.
Via
Talk Markets
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
July 03, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares...
Via
Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
July 03, 2023
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung...
Via
Benzinga
4 Unparalleled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
July 01, 2023
Bargains abound with the innovation-driven Nasdaq Composite still well below its all-time high.
Via
The Motley Fool
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
June 29, 2023
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)...
Via
Benzinga
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
June 26, 2023
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks.
Via
Talk Markets
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
June 26, 2023
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other...
Via
Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
June 26, 2023
The European Union has reco
Via
Benzinga
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
June 23, 2023
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
43
44
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.